Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 2
2011 1
2012 2
2014 2
2015 3
2016 2
2017 5
2018 3
2019 5
2020 7
2021 4
2022 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.
Trimble CL, Morrow MP, Kraynyak KA, Shen X, Dallas M, Yan J, Edwards L, Parker RL, Denny L, Giffear M, Brown AS, Marcozzi-Pierce K, Shah D, Slager AM, Sylvester AJ, Khan A, Broderick KE, Juba RJ, Herring TA, Boyer J, Lee J, Sardesai NY, Weiner DB, Bagarazzi ML. Trimble CL, et al. Among authors: kraynyak ka. Lancet. 2015 Nov 21;386(10008):2078-2088. doi: 10.1016/S0140-6736(15)00239-1. Epub 2015 Sep 17. Lancet. 2015. PMID: 26386540 Free PMC article. Clinical Trial.
Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection.
Jacobson JM, Zahrieh D, Strand CA, Cruz-Correa M, Pungpapong S, Roberts LR, Mandrekar SJ, Rodriguez LM, Boyer J, Marrero I, Kraynyak KA, Morrow MP, Sylvester AJ, Pawlicki JM, Gillespie E, Barranco E, Richmond E, Umar A, Weiner DB, Limburg PJ; Cancer Prevention Network. Jacobson JM, et al. Among authors: kraynyak ka. Cancer Prev Res (Phila). 2023 Mar 1;16(3):163-173. doi: 10.1158/1940-6207.CAPR-22-0217. Cancer Prev Res (Phila). 2023. PMID: 36534786 Free PMC article. Clinical Trial.
Delineating the Cellular Mechanisms Associated with Skin Electroporation.
Schultheis K, Smith TRF, Kiosses WB, Kraynyak KA, Wong A, Oh J, Broderick KE. Schultheis K, et al. Among authors: kraynyak ka. Hum Gene Ther Methods. 2018 Aug;29(4):177-188. doi: 10.1089/hgtb.2017.105. Epub 2018 Aug 10. Hum Gene Ther Methods. 2018. PMID: 29953259 Free PMC article.
Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL.
Bhuyan PK, Dallas M, Kraynyak K, Herring T, Morrow M, Boyer J, Duff S, Kim J, Weiner DB. Bhuyan PK, et al. Among authors: kraynyak k. Hum Vaccin Immunother. 2021 May 4;17(5):1288-1293. doi: 10.1080/21645515.2020.1823778. Epub 2020 Nov 11. Hum Vaccin Immunother. 2021. PMID: 33175656 Free PMC article. Clinical Trial.
SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial.
Kraynyak KA, Blackwood E, Agnes J, Tebas P, Giffear M, Amante D, Reuschel EL, Purwar M, Christensen-Quick A, Liu N, Andrade VM, Diehl MC, Wani S, Lupicka M, Sylvester A, Morrow MP, Pezzoli P, McMullan T, Kulkarni AJ, Zaidi FI, Frase D, Liaw K, Smith TRF, Ramos SJ, Ervin J, Adams M, Lee J, Dallas M, Shah Brown A, Shea JE, Kim JJ, Weiner DB, Broderick KE, Humeau LM, Boyer JD, Mammen MP. Kraynyak KA, et al. J Infect Dis. 2022 Jun 1;225(11):1923-1932. doi: 10.1093/infdis/jiac016. J Infect Dis. 2022. PMID: 35079784 Free PMC article. Clinical Trial.
INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants.
Andrade VM, Christensen-Quick A, Agnes J, Tur J, Reed C, Kalia R, Marrero I, Elwood D, Schultheis K, Purwar M, Reuschel E, McMullan T, Pezzoli P, Kraynyak K, Sylvester A, Mammen MP, Tebas P, Joseph Kim J, Weiner DB, Smith TRF, Ramos SJ, Humeau LM, Boyer JD, Broderick KE. Andrade VM, et al. Among authors: kraynyak k. NPJ Vaccines. 2021 Oct 14;6(1):121. doi: 10.1038/s41541-021-00384-7. NPJ Vaccines. 2021. PMID: 34650089 Free PMC article.
Safety and immunogenicity of VGX-3100 formulations in a healthy young adult population.
Hollenberg RK, Krieger DR, Samuels R, Kraynyak K, Sylvester A, Morrow M, Boyer J, Dallas M, Bhuyan PK. Hollenberg RK, et al. Among authors: kraynyak k. Hum Vaccin Immunother. 2020 Jun 2;16(6):1404-1412. doi: 10.1080/21645515.2019.1695459. Epub 2019 Dec 20. Hum Vaccin Immunother. 2020. PMID: 31860383 Free PMC article. Clinical Trial.
Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer.
Aggarwal C, Cohen RB, Morrow MP, Kraynyak KA, Sylvester AJ, Knoblock DM, Bauml JM, Weinstein GS, Lin A, Boyer J, Sakata L, Tan S, Anton A, Dickerson K, Mangrolia D, Vang R, Dallas M, Oyola S, Duff S, Esser M, Kumar R, Weiner D, Csiki I, Bagarazzi ML. Aggarwal C, et al. Among authors: kraynyak ka. Clin Cancer Res. 2019 Jan 1;25(1):110-124. doi: 10.1158/1078-0432.CCR-18-1763. Epub 2018 Sep 21. Clin Cancer Res. 2019. PMID: 30242022 Free PMC article. Clinical Trial.
CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens.
Shore ND, Morrow MP, McMullan T, Kraynyak KA, Sylvester A, Bhatt K, Cheung J, Boyer JD, Liu L, Sacchetta B, Rosencranz S, Heath EI, Nordquist L, Cheng HH, Tagawa ST, Appleman LJ, Tutrone R, Garcia JA, Whang YE, Kelly WK, Weiner DB, Bagarazzi ML, Skolnik JM. Shore ND, et al. Among authors: kraynyak ka. Mol Ther. 2020 May 6;28(5):1238-1250. doi: 10.1016/j.ymthe.2020.02.018. Epub 2020 Mar 3. Mol Ther. 2020. PMID: 32208168 Free PMC article. Clinical Trial.
32 results